State Street Corp Immunome Inc. Transaction History

State Street Corp

$2.36 Trillion
Q1 2025

A detailed history of State Street Corp transactions in Immunome Inc. stock. As of the latest transaction made, State Street Corp holds 2,640,443 shares of IMNM stock, worth $21.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,640,443

Previous 2,126,835 24.15%

Holding current value

$21.5 Million

Previous $21.8 Million 18.56%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$6.73 - $11.83 $3.46 Million - $6.08 Million	513,608 Added 24.15%	2,640,443 $17.8 Million
Q4 2024 Feb 14, 2025	SELL	$9.11 - $14.53 $552,348 - $880,968	-60,631 Reduced 2.77%	2,126,835 $21.8 Million
Q3 2024 Nov 14, 2024	SELL	$11.7 - $16.51 $2.07 Million - $2.92 Million	-176,768 Reduced 7.48%	2,187,466 $32 Million
Q2 2024 Aug 14, 2024	BUY	$11.54 - $22.11 $25 Million - $47.8 Million	2,163,543 Added 1078.05%	2,364,234 $28.6 Million
Q1 2024 May 15, 2024	BUY	$11.01 - $27.34 $1.87 Million - $4.65 Million	170,100 Added 556.05%	200,691 $4.95 Million
Q4 2023 Feb 14, 2024	BUY	$7.3 - $10.73 $7,300 - $10,730	1,000 Added 3.38%	30,591 $327,000
Q1 2022 May 16, 2022	BUY	$3.88 - $13.99 $10,053 - $36,248	2,591 Added 9.6%	29,591 $168,000
Q4 2021 Feb 14, 2022	BUY	$12.96 - $23.44 $185,328 - $335,192	14,300 Added 112.6%	27,000 $350,000
Q3 2021 Nov 15, 2021	BUY	$12.5 - $27.76 $158,750 - $352,552	12,700 New	12,700 $309,000
Q2 2021 Aug 16, 2021	SELL	$16.33 - $32.33 $531,541 - $1.05 Million	-32,550 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$9.56 - $43.24 $311,178 - $1.41 Million	32,550 New	32,550 $1.1 Million

Others Institutions Holding IMNM

# of Institutions

149

Shares Held

66.3M

Call Options Held

47.3K

Put Options Held

4.31M

View Full List

About Immunome Inc.

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $99M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

More about IMNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Immunome Inc. Transaction History